Do novel risk biomarkers reflect the severity of peripheral arterial disease?

Angiology

Volumn 62, Issue 2, 2011, Pages 126-133

  Khandanpour, Nader ^a,b   Jennings, Barbara ^a   Armon, Matthew P ^b   Wright, Anthony ^c   Willis, Gavin ^b   Clark, Allan ^a   Meyer, Felicity J ^c  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c NORWICH RESEARCH PARK   (United Kingdom)

Author keywords

folate; genetic polymorphism; homocysteine; inflammatory markers; peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; CYANOCOBALAMIN; DIPYRIDAMOLE; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; WARFARIN;

ADJUSTMENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; BETA RHYTHM; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CELL; DISEASE ASSOCIATION; DISEASE SEVERITY; ERYTHROCYTE; FEMALE; GENOTYPE; HUMAN; KNEE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA; PULSE WAVE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BLOOD FLOW VELOCITY; C-REACTIVE PROTEIN; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; VITAMIN B 12;

EID: 78651409990     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710380681     Document Type: Article

References (41)

1. Belch JJ, Topol EJ, Agnelli G., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003 ; 163 (8). 884-892.
2. Völler H. Peripheral arterial disease (PAD): secondary prevention. Dtsch Med Wochenschr. 2002 ; 127 (37). 1870-1872.
3. Whisnant JP Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke. 1997 ; 28 (9). 1840-1844.
4. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E., Turner ST Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003 ; 8 (4). 237-242.
5. Santos S., Rooke TW, Bailey KR, McConnell JP, Kullo IJ Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. Vasc Med. 2004 ; 9 (3). 171-176.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 ; 340 (2). 115-126.
7. Torzewski J. C-reactive protein and atherogenesis: new insights from established animal models. Am J Pathol. 2005 ; 167 (4). 923-925.
8. Wang X., Qin X., Demirtas H., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007 ; 369 (9576). 1876-1882.
9. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003 ; 107 (22). 2864-2869.
10. McNulty H., Pentieva K., Hoey L., Ward M. Homocysteine, B-vitamins and CVD. Proc Nutr Soc. 2008 ; 67 (2). 232-237.
11. Watkins D., Ru M., Hwang HY, et al. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am J Hum Genet. 2002 ; 71 (1). 143-153.
12. Vaughn JD, Bailey LB, Shelnutt KP, et al. Methionine synthase reductase 66A->G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C->T variant. J Nutr. 2004 ; 134 (11). 2985-2990.
13. Khandanpour N., Willis G., Meyer FJ, et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J Vasc Surg. 2009 ; 49 (3). 711-718.
14. Hooi JD, Stoffers HE, Kester AD, van RJ, Knottnerus JA Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle-brachial pressure index. Med Decis Making. 2002 ; 22 (2). 99-107.
15. Liu DH, Wang Y., Liao XX, et al. Increased brachial-ankle pulse wave velocity is associated with impaired endothelial function in patients with coronary artery disease. Chin Med J (Engl). 2006 ; 119 (22). 1866-1870.
16. Amoh-Tonto CA, Malik AR, Kondragunta V., Ali Z., Kullo IJ Brachial-ankle pulse wave velocity is associated with walking distance in patients referred for peripheral arterial disease evaluation. Atherosclerosis. 2009 ; 206 (1). 173-178.
17. Yokoyama H., Shoji T., Kimoto E., Shinohara K., Tanaka S., Koyama H., Emoto M., Nishizawa Y. Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease. J Atheroscler Thromb. 2003 ; 10 (4). 253-258.
18. Kanda T., Nakamura E., Moritani T., Yamori Y. Arterial pulse wave velocity and risk factors for peripheral vascular disease. Eur J Appl Physiol. 2000 ; 82 (1-2). 1-7.
19. Roeren T., LeVeen RF, Nugent L. Photoplethysmographic documentation of improved microcirculation after pentoxifylline therapy. Angiology. 1988 ; 39 (11). 929-933.
20. Khawaja FJ, Bailey KR, Turner ST, Kardia SL, Mosley TH Jr, Kullo IJ Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin Proc. 2007 ; 82 (6). 709-716.
21. Khandanpour N., Armon MP, Jennings B., et al. Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. Br J Surg. 2009 ; 96 (9). 990-998.
22. Yamashina A., Tomiyama H., Takeda K., et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002 ; 25 (3). 359-364.
23. O'Broin S., Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol. 1992 ; 45 (4). 344-347.
24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107 (3). 499-511.
25. Iwashima Y., Horio T., Suzuki Y., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis. 2006 ; 188 (2). 384-390.
26. Tzoulaki I., Murray GD, Lee AJ, Rumley A., Lowe GD, Fowkes FG Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh artery study. Eur Heart J. 2007 ; 28 (3). 354-362.
27. Lee AJ, MacGregor AS, Hau CM, et al. The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study. Br J Haematol. 1999 ; 105 (3). 648-654.
28. McDermott MM, Guralnik JM, Corsi A., et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 2005 ; 150 (2). 276-281.
29. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002 ; 106 (12). 1447-1452.
30. Arnaud C., Burger F., Steffens S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005 ; 25 (6). 1231-1236.
31. Meigs JB, Hu FB, Rifai N., Manson JE Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004 ; 291 (16). 1978-1986.
32. Bolton CH, Downs LG, Victory JG, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001 ; 16 (6). 1189-1197.
33. Mayer O., Filipovský J., Dolejsová M., Cí fková R., Simon J., Bolek L. Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. J Hum Hypertens. 2006 ; 20 (4). 267-271.
34. Bortolotto LA, Safar ME, Billaud E., et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension. 1999 ;34(4 pt 2). 837-842.
35. Levy D., Hwang SJ, Kayalar A., et al. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham heart study. Circulation. 2007 ; 115 (24). 3079-3085.
36. Hart SR, Mangoni AA, Swift CG, Jackson SH Effect of methionine loading on pulse wave analysis in elderly volunteers. Postgrad Med J. 2006 ; 82 (970). 524-527.
37. Daskalopoulou SS, Pathmarajah M., Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008 ; 72 (3). 441-448.
38. Morrison HI, Schaubel D., Desmeules M., Wigle DT Serum folate and risk of fatal coronary heart disease. JAMA. 1996 ; 275 (24). 1893-1896.
39. Fowkes FG, Lee AJ, Hau CM, Cooke A., Connor JM, Lowe GD Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh artery study. Atherosclerosis. 2000 ; 150 (1). 179-185.
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497.
41. Hiatt WR Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 ; 344 (21). 1608-1621.